Report of Foreign Issuer (6-k)
December 04 2017 - 7:02AM
Edgar (US Regulatory)
United
States
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
OF THE SECURITIES EXCHANGE ACT OF 1934
For the Month of December, 2017
Commission File Number: 001-35892
GW PHARMACEUTICALS PLC
(Translation of registrant’s name
into English)
Sovereign House
Vision Park
Histon
Cambridge CB24 9BZ
United Kingdom
(Address of principal executive offices)
Indicate by check mark whether the registrant
files or will file annual reports under cover of Form 20-F or Form 40-F.
Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
¨
Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):
¨
Other Events
On December 4, 2017, GW Pharmaceuticals
plc (the “Company”) issued a press release announcing its fourth quarter and fiscal year-end 2017 financial results
and operational progress and details of a conference call to be held at 7:30 a.m. EST on December 4, 2017 to discuss the results
and operational progress. The press release is attached as Exhibit 99.1 and is incorporated by reference herein.
The Company posted presentations at
the American Epilepsy Society (AES) annual meeting held in Washington, D.C. from December 1 to December 5, 2017 with data
from pivotal trials, the Company’s expanded access program and non-clinical research. There were 25 presentations, 22 of
which were authored by the Company. Additionally, on December 4, 2017, the Company is hosting a scientific exhibit that
covers all of the data presented over the course of the AES meeting. The presentation materials are attached as Exhibit 99.2
and are incorporated by reference herein.
The information contained in Exhibits 99.1
and 99.2 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended
(the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the
Exchange Act, unless expressly set forth by specific reference in such a filing.
Exhibits
99.1 Press Release dated December 4, 2017
99.2 Presentation Materials.
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly
authorized.
|
GW Pharmaceuticals plc
|
|
|
|
|
By:
|
/s/ Adam George
|
|
Name:
|
Adam George
|
|
Title:
|
Secretary
|
|
|
|
Date: December 4, 2017
|
|
|